Inhaled Nitric Oxide Delivery: Past, Present, and Future
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
Clinical trial and real-world data provide evidence that inhaled nitric oxide is effective for reducing pulmonary hypertension in the perioperative setting.
Results of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
For patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read MorePatients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read MorePatients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read MoreFor patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreIn obstructive sleep apnea patients with high blood pressure resistant to treatment, the more severe their OSA, the higher their blood pressure.
Read MoreScientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read MoreSoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read MorePatients at greatest risk of dying from PAH may be identified through cardiac MRI and the information the noninvasive scan provides about the functional level of the heart’s right ventricle.
Read MoreIn addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read MoreTreatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read MoreDevelopment of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.
Read More